2199: Donor Cellular Infusion

This Donor Cellular Infusion (2199) Form must be completed for all recipients who receive either:

• A donor lymphocyte infusion, a type of cell therapy
• An allogeneic boost, a type of HCT
  

These two types of infusions are referred to as “donor cellular infusions” for the purpose of this form. See Appendix D: How to Distinguish Infusion Types for more information on how to distinguish infusion types.

!One Indication for CIBMTR Data Reporting (2814) Form per Reporting Period
When multiple subsequent infusions occur, there should be a single Indication for CIBMTR Data Reporting (2814) Form per reporting period. If multiple DLIs are given in a reporting period, edit the Indication for CIBMTR Data Reporting (2814) Form to update the number of reported DLIs.

*On Demand DLI Reporting
DLIs can be reported prior to the Post-TED (2450) or Post-Infusion Follow-Up (2100) Form due date by creating an Indication for CIBMTR Data Reporting (2814) Form on demand.
When the Post-TED (2450) or Post-Infusion follow up (2100) Form is completed at the due date, and no other infusions were given in the reporting period, report the DLI as a subsequent infusion, which will create a new Indication for CIBMTR Data Reporting (2814) Form. Submit a ticket via CIBMTR Center Support to request the form be made NRQ.

Donor Lymphocyte Infusion (DLI)

Donor lymphocyte infusions (DLI) are a type of cell therapy and are defined for CIBMTR reporting purposes as:

• The infusion must be post-allogeneic HCT and probably from the same donor*
• Product must be lymphocytes only
• Product cannot be genetically modified

*This is the most common scenario right now, but in the future, DLI products may be obtained from a different donor.

For recipients of any other type of cellular therapy, such as CAR-T cells, tumor-infiltrating lymphocytes, cytotoxic T cells, or any cellular therapy product that is genetically modified, complete the Pre-CTED (4000) Form.

Multiple DLIs within the same reporting period require a separate Donor Cellular Infusion (2199) form for each infusion.
This form will come due for recipients post-HCT when DLI are reported on the Indication for CIBMTR Data Reporting (2814) Form after a subsequent infusion is reported on the Post-TED (2450) or Post-Infusion Follow-Up (2100) Form.

At the time of completing the Indication for CIBMTR Data Reporting (2814) Form, the total number of DLIs received in that reporting period are reported on the form. The number of infusions reported will make the same number of Donor Cellular Infusion (F2199) Forms due in FormsNet3^SM.

The Post-TED (2450) / Post-Infusion Follow-Up (2100) / Post-CTED (4100) Forms will not be completed early to report DLIs given in the reporting period. See Reporting Instruction Overview, Contact Dates for more information on reporting subsequent infusions and contact dates.

Follow up reporting of the prior infusion will not be interrupted and combined follow up rules do not apply to DLIs.

*On Demand Allogeneic Boost Reporting
Allogeneic boosts can be reported prior to the Post-TED (2450) or Post-Infusion follow up (2100) Form due date by creating an Indication for CIBMTR Data Reporting (2814) Form on demand.
When the Post-TED (2450) or Post-Infusion Follow-Up (2100) Form is completed at the due date, and no other infusions were given in the reporting period, report the allogeneic boost as a subsequent infusion, which will create a new Indication for CIBMTR Data Reporting (2814) Form. Submit a ticket via CIBMTR Center Support to request the form be made NRQ.

Allogeneic Boosts

Allogeneic boosts are a type of HCT and are defined for CIBMTR reporting purposes as:

• The infusion must be post-allogeneic HCT and from a prior allogeneic donor
• Indication for infusion is poor graft function / insufficient hematopoietic recovery
• Product contains CD34+ cells
• Product cannot be genetically modified

For any allogeneic infusion with the indication other than poor graft function / insufficient hematopoietic recovery (e.g. graft failure), complete the Pre-TED (2400) and Disease Classification (2402) Forms.

Each allogeneic boost requires a separate Donor Cellular Infusion (2199) Form for each infusion. This form will come due for recipients post-HCT when an allogeneic boost is reported on the Indication for CIBMTR Data Reporting (2814) Form after a subsequent infusion is reported on the Post-TED (2450) or Post-Infusion Follow-Up (2100) Form.

The Post-TED (2450) / Post-Infusion Follow-Up (2100) will not be completed early to report allogeneic boosts given in the reporting period. See Reporting Instruction Overview, Contact Dates for more information on reporting subsequent infusions and contact dates

Follow up reporting of the prior infusion will not be interrupted and combined follow up rules do not apply to allogeneic boosts.

Links to Sections of Form:
Q1 – 4: Donor Information
Q5 – 39: Donor Cellular Infusion

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

To reference the historical Manual Change History for this form, reference the retired manual section on the Retired Forms Manuals webpage

Date	Manual Section	Add/Remove/Modify	Description
10/24/2025	2199: Donor Lymphocyte Infusion	Modify	Version 2 of the 2199: Donor Lymphocyte Infusion section of the Forms Instruction Manual released. Version 2 corresponds to revision 2 of the Form 2199.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.